Daily Trades

I recommend selling shares of ON Semiconductor (SYM: ON) here at $78.95, a 116% gain from our recommended price of $36.44. 
An aging population is demanding better treatment in an effort to live longer lives (I'm beginning to count myself among that population). As we've detailed in these pages over the years, there's incredible new innovation in gene therapies, immuno-oncology, precision medicine, machine-learning drug discovery, and treatments for unmet medical needs, such as Geographic Apathy.
I have an exciting recommendation for you this month: organ transplant firm, TransMedics (SYM: TMDX). It’s a bit outside of our normal focus on oncology and rare disease firms.
On November 18, MEI Pharma (SYM: MEIP) and their Japanese Big Pharma giant Kyowa Kirin announced solid results for their Lymphoma drug, zandelisib. 
Education is witnessing a massive, transformational shift. In fact, the online learning category is expected to grow more than five times over the next seven years, according to IPO Edge, which is more than two times faster that e-commerce growth between 2014 and 2019.
Wanted to give you all a quick update on Clovis (SYM: CLVS) and MEI Pharma (SYM: MEIP). The iron rule of biotech investing is to bet on the science.

deal of the month

best growth stocks

Alliance

Bundle package – lifetime subscriptions for all products

Categories

Recent posts

Tags

Connect with Us

I recommend selling shares of ON Semiconductor (SYM: ON) here at $78.95, a 116% gain from our recommended price of $36.44. 
An aging population is demanding better treatment in an effort to live longer lives (I'm beginning to count myself among that population). As we've detailed in these pages over the years, there's incredible new innovation in gene therapies, immuno-oncology, precision medicine, machine-learning drug discovery, and treatments for unmet medical needs, such as Geographic Apathy.
I have an exciting recommendation for you this month: organ transplant firm, TransMedics (SYM: TMDX). It’s a bit outside of our normal focus on oncology and rare disease firms.
On November 18, MEI Pharma (SYM: MEIP) and their Japanese Big Pharma giant Kyowa Kirin announced solid results for their Lymphoma drug, zandelisib. 
Education is witnessing a massive, transformational shift. In fact, the online learning category is expected to grow more than five times over the next seven years, according to IPO Edge, which is more than two times faster that e-commerce growth between 2014 and 2019.
Wanted to give you all a quick update on Clovis (SYM: CLVS) and MEI Pharma (SYM: MEIP). The iron rule of biotech investing is to bet on the science.

Get FREE Daily Stock Tips

Join and receive market insider stock picks, trade alerts and unique investing insights
This field is for validation purposes and should be left unchanged.
By clicking the "Subscribe" button you are accepting our Terms of Use and Privacy Policy.

Join Waitlist

We’re sorry, but due to the popularity of our services, we have reached our max number of subscribers and are not currently accepting more. If spots become available, we will be sure to contact you. Please join the waitlist below.
Thank You!

"*" indicates required fields

Name*
This field is for validation purposes and should be left unchanged.